Trials / Completed
CompletedNCT00429936
Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 245 (actual)
- Sponsor
- Sirion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fenretinide | Once daily 30 minutes after the evening meal for 24 months |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2007-02-01
- Last updated
- 2010-06-22
Source: ClinicalTrials.gov record NCT00429936. Inclusion in this directory is not an endorsement.